Morgan Stanley’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q3 | – | Sell |
-18,226
| Closed | -$273K | – | 6676 |
|
|
2016
Q2 | $273K | Sell |
18,226
-114,776
| -86% | -$1.47M | ﹤0.01% | 4782 |
|
|
2016
Q1 | $1.62M | Sell |
133,002
-22,913
| -15% | -$321K | ﹤0.01% | 3520 |
|
|
2015
Q4 | $2.48M | Buy |
155,915
+86,578
| +125% | +$1.36M | ﹤0.01% | 3313 |
|
|
2015
Q3 | $1.06M | Buy |
69,337
+23,814
| +52% | +$515K | ﹤0.01% | 4054 |
|
|
2015
Q2 | $1.11M | Sell |
45,523
-1,726,347
| -97% | -$41.4M | ﹤0.01% | 4122 |
|
|
2015
Q1 | $41.2M | Sell |
1,771,870
-2,007,552
| -53% | -$53.1M | 0.02% | 964 |
|
|
2014
Q4 | $94.9M | Buy |
3,779,422
+29,760
| +0.8% | +$873K | 0.03% | 536 |
|
|
2014
Q3 | $117M | Sell |
3,749,662
-2,358
| -0.1% | -$63.9K | 0.04% | 460 |
|
|
2014
Q2 | $97M | Sell |
3,752,020
-3,456
| -0.1% | -$76.8K | 0.04% | 527 |
|
|
2014
Q1 | $87.8M | Sell |
3,755,476
-19,850
| -0.5% | -$434K | 0.04% | 518 |
|
|
2013
Q4 | $95.8M | Sell |
3,775,326
-94,044
| -2% | -$2.12M | 0.04% | 473 |
|
|
2013
Q3 | $78.9M | Sell |
3,869,370
-419,703
| -10% | -$9.34M | 0.04% | 490 |
|
|
2013
Q2 | $90M | Buy |
+4,289,073
| New | +$76.7M | 0.05% | 437 |
|
Morgan Stanley's SGNT Position: Q3 2016 in Review
Morgan Stanley sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 18,226 shares — an estimated $273K sold.
Morgan Stanley first reported a position in SGNT in Q2 2013 and held it in 13 quarters. The position peaked at $117M in Q3 2014. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.
- Morgan Stanley reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
- Morgan Stanley sold 18,226 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $273K.
- Morgan Stanley first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 13 quarters.
- Morgan Stanley's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $117M in Q3 2014.
- 0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.
Based on Morgan Stanley's 13F filing for Q3 2016, filed 10 Nov 2016.